TORONTO, May 9, 2016 /PRNewswire/ - Transition
Therapeutics Inc. ("Transition" or the "Company") (NASDAQ:
TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss Third Quarter Fiscal
2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer
of the Company, will host the call. Transition will announce
its financial results for this period in a press release to be
issued prior to the call. In order to participate in the
conference call, please call (800) 698-9012 (North America) and (303) 223-4374
(International). A webcast is also available at
www.transitiontherapeutics.com A replay of the conference
call will be available on Transition's website for seven days
following the call.
About Transition
Transition is a biopharmaceutical development company, advancing
novel therapeutics for CNS, metabolic diseases and androgen
deficiency indications. The Company's wholly-owned subsidiary,
Transition Therapeutics Ireland Limited has two development
programs: CNS drug candidate ELND005 for the treatment of
Alzheimer's disease and Down syndrome; and selective androgen
receptor modulator drug candidate TT701. Transition's lead
metabolic drug candidate is TT401 for the treatment of type 2
diabetes and accompanying obesity. The Company's shares are listed
on the NASDAQ under the symbol "TTHI" and the Toronto Stock
Exchange under the symbol "TTH". For additional information about
the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases
should be considered accurate only as of the date of the release
and may be superseded by more recent information we have disclosed
in later press releases, filings with the OSC, SEC or otherwise.
Except for historical information, this press release may contain
forward-looking statements, relating to expectations, plans or
prospects for Transition, including conducting clinical trials and
potential efficacy of its products. These statements are based upon
the current expectations and beliefs of Transition's management and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
factors beyond Transition's control and the risk factors and other
cautionary statements discussed in Transition's quarterly and
annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.